Result description
Within the H2020 VES4US and ongoing H2020 BOW projects, key attributes of raw and loaded microalgae-derived extracellular vesicles (named algosomes) and their production process were validated at lab scale (TRL4), achieving significant milestones:
– Established microalgae cultivation using photoautotrophic bioreactors, optimizing quality-based productivity by TFF EV-isolation.
– Full characterization of algosomes.
– Quality control: Integrated QC&QA processes ensuring consistent quality.
– Preclinical demonstration: Biocompatibility, safety, and uptake were confirmed in vivo using the Caenorhabditis elegans and mouse models
– Algosome functionalization and loading: Loaded algosomes with hydrophobic/hydrophilic molecules, RNAs, and large proteins, achieving high loading efficiency and validated efficacy in vitro and in vivo. Targeted localization in skin and bone was observed in mouse biodistribution studies.
– EVE Biofactory incorporation: Launched in September 2022, EVE Biofactory recruited employees, secured IP transfer, filed an additional patent, and signed agreements with a cosmetic company, generating initial revenues.
Addressing target audiences and expressing needs
- Grants and Subsidies
- Business Angels
- Venture Capital
We are specifically looking for strategic partners and investors to support EVEBiofactory in achieving its ambitious goals. Our target audience includes pharmaceutical companies, biotech investors, and cosmeceutical developers interested in cutting-edge nanotechnology for therapeutic and skincare applications. We need €200k by 2025 for safety assessments and €800k by 2026 for efficacy trials and production optimization. Additionally, we seek collaborations for scaling up production to GMP standards and developing new EV-based therapies and cosmetic products.
- Public or private funding institutions
- Other Actors who can help us fulfil our market potential
- Private Investors
R&D, Technology and Innovation aspects
We have validated key attributes of microalgae-derived extracellular vesicles (algosomes) at TRL4, achieving significant milestones in isolation, characterization, quality control, preclinical demonstration, and engineering. Our next R&D stage involves scaling up production, optimizing processes for GMP compliance, and advancing to clinical trials. Our target audiences are actors who can help us fulfill our market potential.
EVEBiofactory’s business exemplifies scalability by adapting to changing customer needs and increasing demand while maintaining profitability and high-quality standards. Our innovative algosome production technology is flexible and can be tailored to various therapeutic and cosmeceutical applications, ensuring relevance in a dynamic market. For investors, EVEBiofactory’s scalability means we can increase revenue per unit of resource by making our processes more efficient and improving our unit economics over time. While growth involves raising funds to recruit sales people, scaling for us means optimizing our resources to maximize output without compromising algosome quality. This strategic focus allows us to do more with less, driving sustainable growth and competitive advantage in the bio-nanotechnology sector.
EVEBiofactory’s business model and manufacturing bioprocesses are built on replicability, ensuring our algosome technology can be consistently replicated, sold, and eventually outsourced with the same high standards across multiple markets. Our scalable production processes and rigorous quality control systems enable us to maintain uniformity and reliability in our products. This capability allows us to serve an ever-growing customer base, providing the same exceptional therapeutic and cosmeceutical solutions to an expanding range of clients, regardless of location or scale. Our commitment to replicability ensures that every customer receives the same high-quality product, fostering trust and satisfaction in diverse markets.
EVEBiofactory’s business model exemplifies economic and environmental sustainability by leveraging green production methods through the use of microalgae-producing cells. Our algosome technology harnesses the natural capabilities of microalgae, offering a renewable and eco-friendly alternative to traditional synthetic methods. This approach not only reduces environmental impact but also aligns with the principles of a sustainable business model by creating and delivering exceptional value to our customers while regenerating natural, social, and economic capital. By integrating sustainable practices into our core operations, we ensure that our business adds value to stakeholders, the environment, and society. Our commitment to green production demonstrates our dedication to maintaining ecological balance and promoting long-term sustainability in the bio-nanotechnology sector.
